Contents

Welcome address XI
J. Rosenthal

Pathophysiology of hypertension with regard to calcium and the sympathetic nervous system 1
P.A. van Zwieten

Pharmacotherapy

Pharmacological basis for the treatment of hypertension with calcium antagonists 15
H. Scholz

Drug interactions during oral antihypertensive therapy with calcium antagonists 24
N. Rietbrock and B.G. Woodcock

The effects of 240 mg of verapamil in sustained-release form on the 24-hour blood pressure profile in essential hypertension 50
D. Edmonds, P. Baumgart, W. Vetter and H. Vetter

Plasma concentration and blood pressure effect of a sustained-release verapamil preparation (240 mg Isoptin® RR) 56
H. Pozenel

Sustained-release verapamil in ambulant patients with hypertension 66
B. König

Differential therapy with calcium antagonists 73
F. Bender

Summary of the discussion 78
J. Rosenthal

Calcium antagonists and prevention of target organ damage

The actions of verapamil on the model of arteriosclerosis 83
E. Betz, H. Hämmerle, D. Kling, D. Lenke and C.D. Müller

The influence of long-term therapy with verapamil on the development of coronary artery stenosis 97
G. Kober, T. Nickelsen, B. Jakobs and M. Kaltenbach

Calcium antagonists and regional myocardial perfusion. A tomoscintigraphic investigation during treatment with verapamil 106
H. Eichstädt, M. Gutmann, M. Langer, R. Felix and H. Schmutzler

Intravenous administration of verapamil in myocardial infarction 120
W.-D. Bussmann and H. Klepzig jr

Calcium antagonists in cerebrovascular diseases 129
W.-D. Heiss

Hypertension and coronary heart disease 141
D. Klaus

Summary of the discussion 162
F. Bender

Treatment with calcium antagonists

Drug therapy of mild hypertension 167
A. Distler

Treatment of hypertension with sustained-release verapamil 177
G.G. Belz and G. Spies

Calcium antagonists in impaired renal function and hypertension 190
U. Heidland, W. Riegel, E. Heidbreder, W.H. Hörl and A. Heidland

Calcium antagonists in hypertension and coronary heart disease. Results of a double-blind, randomized, placebo-controlled study with sustained-release verapamil 209
U. Brügmann

Antihypertensive therapy and lipid metabolism 220
W. Krone, D. Müller-Wieland and H. Greten

Status of calcium antagonists in the treatment of hypertension 228
W. Kaufmann

Summary of the discussion 237
A. Distler

Summary of the round table discussion 240
J. Rosenthal

Concluding remarks 243
J. Rosenthal

Author index 247

Subject index 248